Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071750 | 1.00 | ABCC4 (0.43) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL27039983 | 0.88 | MAPT (0.54) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL4017942 | 0.86 | MAPT (0.50) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL9789270 | 0.84 | TSHR (0.42) | ABCC4MAPTALDH1A1LMNALPAR2 | |
| SCHEMBL9789360 | 0.84 | TSHR (0.42) | ABCC4MAPTALDH1A1LMNALPAR2 | |
| SCHEMBL4013371 | 0.82 | MAPT (0.48) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL2135399 | 0.80 | ALDH1A1 (0.38) | ABCC4MAPTALDH1A1LMNATSHR | |
| SCHEMBL16421159 | 0.79 | TSHR (0.57) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL17954034 | 0.79 | ACLY (0.46) | ABCC4MAPTALDH1A1LMNAACLY | |
| SCHEMBL21168183 | 0.79 | MAPT (0.71) | ABCC4MAPTALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555571-B2 | Hormone inhibitor; sexual disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1240156-A4 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-1240156-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042237-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | ESR2, GPER1, NR5A1 | ABCC4 1460/4885MAPT 2698/4885ALDH1A1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.